|Bid||13.97 x 900|
|Ask||25.00 x 3100|
|Day's Range||13.79 - 14.70|
|52 Week Range||13.79 - 37.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Subscribe to Yahoo Finance Plus to view Fair Value for JANXLearn more
SAN DIEGO, January 05, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]